Medical device company Artivion (NYSE: AORT) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 11.3% year on year to $125.8 million. The company expects the full year’s revenue to be around $488 million, close to analysts’ estimates. Its non-GAAP profit of $0.13 per share was 34.5% above analysts’ consensus estimates.

Is now the time to buy AORT? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Artivion’s second quarter results were well received by the market, with performance driven by accelerating growth in its stent graft and On-X heart valve portfolios. Management credited strong On-X adoption, improved stent graft set sales, and a return to growth across international markets as key drivers behind the positive momentum. CEO Pat Mackin highlighted the recent FDA approval of the AMDS hybrid prosthesis and the acquisition of Endospan’s NEXUS system as important milestones, noting, “We are encouraged by our enduring fundamental strength and increasingly strong competitive advantages within this segment.”

Looking ahead, Artivion’s outlook is shaped by anticipated expansion in its U.S. aortic product platforms and the ramp-up of recently acquired and approved devices. Management believes that the removal of regulatory hurdles for AMDS and the upcoming U.S. launch of NEXUS will accelerate adoption and drive growth. CFO Lance Berry emphasized the impact of new product launches, stating, “We expect sequential improvements through the back half of the year as our U.S. AMDS and U.S. On-X sales accelerate.” Pipeline progress, particularly with the ARTISAN clinical trial, is also expected to support long-term market expansion.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to robust product adoption in core portfolios, successful execution of recent acquisitions, and progress in clinical trials that underpin future growth.

• Stent graft acceleration: Stent graft revenues grew 12% year-over-year, with management highlighting both set sales and implant trends as indicators of strengthening customer adoption, particularly following the FDA approval of AMDS.
• On-X valve share gains: The On-X mechanical heart valve portfolio delivered 18% growth, driven by new U.S. market segments as recent clinical data favoring mechanical over bioprosthetic valves in younger patients supported broader adoption and physician confidence.
• NEXUS acquisition completed: The acquisition of Endospan and its NEXUS Aortic Arch Stent Graft System solidified Artivion’s position as the only company with a complete aortic arch product lineup, with management stressing NEXUS’s potential as a platform for multiple future regulatory submissions.
• Tissue business supply constraints: While tissue processing revenue rose modestly, management reiterated that supply, not demand, remains the primary bottleneck for growth in this segment, pointing to strong clinical data as a foundation for future expansion once supply improves.
• R&D and integration spending: Increased research and development expense reflected investments in the NEXUS pipeline and integration costs, impacting operating margins but supporting long-term strategic objectives focused on market and product expansion.

Drivers of Future Performance

Artivion expects growth to be led by new product launches and expanded U.S. access, though investments in commercial infrastructure and R&D will influence margins.

• AMDS and NEXUS ramp-up: Management sees the recent full FDA approval for AMDS and the upcoming U.S. NEXUS launch as key revenue drivers, anticipating accelerated account conversions and broader adoption as regulatory hurdles are removed and messaging improves.
• Continued On-X expansion: Ongoing education of both cardiac surgeons and cardiologists about the benefits of On-X in patients under 65 is expected to drive further U.S. and international market share gains, supported by recent clinical publications and targeted marketing efforts.
• Margin and cash flow considerations: While product adoption and portfolio breadth are expected to drive top-line growth, R&D, integration, and launch expenses—especially for NEXUS—will pressure margins and free cash flow in the near term, with management expecting improvement as investments normalize post-launch.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be monitoring (1) the pace of AMDS adoption and account conversions following its full U.S. approval, (2) progress toward the commercial launch of NEXUS in January 2027, including salesforce build-out and value analysis committee approvals, and (3) the continued expansion of On-X into new patient segments. Additional markers include supply chain normalization in the tissue business and ongoing enrollment in the ARTISAN clinical trial.

Artivion currently trades at $27.29, up from $26.58 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

Stocks That Trumped Tariffs

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.